These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors]. Qiao J; Chen W Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):806-10. PubMed ID: 22008111 [No Abstract] [Full Text] [Related]
24. [Molecular diagnostics in lung carcinoma for therapy stratification]. Heukamp LC; Büttner R Pathologe; 2010 Feb; 31(1):22-8. PubMed ID: 19997736 [TBL] [Abstract][Full Text] [Related]
25. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982 [TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Woo HS; Ahn HK; Lee HY; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK Invest New Drugs; 2014 Dec; 32(6):1311-5. PubMed ID: 25146938 [TBL] [Abstract][Full Text] [Related]
27. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Oda N; Hotta K; Yoshioka H; Kudo K; Ichihara E; Kato Y; Ninomiya K; Minami D; Ninomiya T; Kubo T; Ohashi K; Sato A; Takigawa N; Tabata M; Tanimoto M; Kiura K Cancer Chemother Pharmacol; 2016 Nov; 78(5):941-947. PubMed ID: 27590708 [TBL] [Abstract][Full Text] [Related]
33. EGFR mutation and response of lung cancer to gefitinib. Toyooka S; Kiura K; Mitsudomi T N Engl J Med; 2005 May; 352(20):2136; author reply 2136. PubMed ID: 15901872 [No Abstract] [Full Text] [Related]
34. ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations. Wang Z; Li Z; Ding X; Shen Z; Liu Z; An T; Duan J; Zhong J; Wu M; Zhao J; Zhuo M; Wang Y; Wang S; Sun Y; Bai H; Wang J Sci Rep; 2015 Jun; 5():11392. PubMed ID: 26096604 [TBL] [Abstract][Full Text] [Related]
35. Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib. Chic N; Mayo-de-Las-Casas C; Reguart N J Thorac Oncol; 2017 Jun; 12(6):e78-e80. PubMed ID: 28532569 [No Abstract] [Full Text] [Related]
36. The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Chang AY Expert Opin Investig Drugs; 2008 Mar; 17(3):401-11. PubMed ID: 18321238 [TBL] [Abstract][Full Text] [Related]
37. Clairvoyance or reliable prediction of the future? van Zandwijk N; van de Vijver MJ Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538 [No Abstract] [Full Text] [Related]
38. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Biaoxue R; Shuanying Y; Wei L; Wei Z; Zongjuan M Curr Med Res Opin; 2012 Oct; 28(10):1699-708. PubMed ID: 22978775 [TBL] [Abstract][Full Text] [Related]
39. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. Doss GP; Rajith B; Chakraborty C; NagaSundaram N; Ali SK; Zhu H Sci Rep; 2014 Aug; 4():5868. PubMed ID: 25091415 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]